
Lifileucel Paves the Way for Evolving Treatment Approaches After PD-1 Inhibition in Advanced Melanoma
The swath of agents and regimens approved for the first-line treatment of patients with advanced melanoma has muddied second-line treatment decision-making for this patient population, according to Justin Moser, MD, who added that past and ongoing clinical …